Case Summary:

Our client, a research assistant professor in drug discovery from India was a well-known figure in her area of expertise. Her research in the field has been responsible for several improvements in the drug composition specifically for Tuberculosis. She is especially well-known for studying bacterial multicellular behaviors, selecting preclinical drug candidates, identifying protein targets, and designing in vitro and in vivo assays against the TB-causing pathogen mycobacteria and other bacteria. Furthermore, her work has been commercialized by a well-known drug manufacturer and implemented by a not-for-profit partnership dedicated to the discovery and development of new, faster-acting, and affordable tuberculosis medicines. These scientific achievements affirmed her stature as a leading researcher in drug discovery for us at NAILG when she came to us seeking help with her EB1-A (Alien of Extraordinary Ability) petition.

Our team was quick to respond, and after a detailed brief of the action plan, she settled on upgrading her case for premium processing. This is how her case could get approval in just 49 days. Our firm, having ascertained that her case was of value, prepared a convincing petition and put it together with the necessary documents. This included the client’s CV, her academic and professional certificates, transcripts, and letters of recommendation. We had asked her to get at least 4 separate letters of support, 2 of which came each from dependent and independent sources. These helped immensely in proving the value of her research to the adjudicating bench at USCIS.

Here are a few excerpts from these letters of recommendation:

“[The client’s] prior research on biofilms has helped to demystify their formation and even aid in prevention by determining which chemical structural elements expressly and effectively inhibited cellular aggregation and swarming motility, exposing bacteria to antibiotic action and improving health for countless American patients.”

“[The client] has achieved major advances with her modernization and optimization of in vitro assays and other methods that have streamlined TB drug discovery, revealing new compounds for others in the field to study. This is an ongoing and worthwhile effort producing results that the United States will benefit greatly from through continued scientific advances and economic savings.”

We were able to show that with 19 publications and 2 U.S. patents, she stood an inch taller than most in her field. This was bolstered by 238 citations coming from far and wide across the world’s leading institutions. She had also had the opportunity to conduct 18 peer reviews for influential journals in his field. In addition, her work has received funding from 2 leading institutes in the country, namely the National Science Foundation and the U.S. Environmental Protection Agency.

These supporting arguments helped her claim to the EB1-A category. We are glad and proud to have had this opportunity to represent her at USCIS. We also thank her for retaining us for her NIW (National Interest Waiver) petition. We wish her good luck in all her future endeavors.